MarketsandMarkets ImmunoBio Series 2024

WHAT TO EXPECT

Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B & C- Next Gen Immuno-Oncology Conference

Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

Preclinical and Translational Immuno-Oncology Developments
Next Gen Antibodies and Targeted Therapies
Immune Checkpoint Inhibitors and Combination Therapies
Tumor Microenvironment and Cancer Biomarkers
CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
Cancer Vaccines and Cancer Microbiome
Personalizing Cancer Treatment- Challenges and Opportunities

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation- Reserved Slot for Platinum Sponsor	09:00 - 09:30
Advancing Digital Pathology in biomarker identification and drug discovery	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Reserved Slot for Silver Sponsor	11:15 - 11:45
Functional biomarker assay development for cancer treatment	11:45 - 12:15
Sample quality strategies, operations and patient centricity for biomarker analysis Debora Souza Da Costa, Biosample Operations Specialist, Roche	12:15 - 12:45
Use of biomarkers in clinics-success and challenges of getting a good biomarker	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE
Solution Provider Presentation	14:15 - 14:45
AI for proteomics and biomarker discovery	14:45 - 15:15
Why is monitoring predictive biomarker data so difficult for big pharma?	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Patient Identification and Stratification applying predictive models	16:30 - 17:00
Use of Real-World Evidence in discovery of digital biomarkers	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30
Drinks Reception & Networking	17:30 - 17:30
End of Day 1	17:30 - 17:35

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
NEW ANTIBODIES DEVELOPMENTS AND UPDATES
Keynote Presentation- Reserved Slot for Platinum Sponsor	09:00 - 09:30
IgE Immunotherapy from Concept to Translation Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Targeting myeloid cells to augment antibody immunotherapy Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK	11:15 - 11:45
Recombinant antibodies for Immunotherapy	11:45 - 12:15
Challenges in the clinical development of ADC’s	12:15 - 12:45
Novel Bispecific PD-1 antibody therapeutic approach in solid tumours	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Role of Cancer Microbiome in IO	15:15 - 15:45
NEW ANTOBODY FORMATS AND TUMOR MICRO-ENVIROMENT
Solution Provider Presentation	14:15 - 14:45
Bispecific antibody programme Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK	14:45 - 15:15
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Recombinant antibodies for immunotherapy	16:30 - 17:00
Panel Discussions - Innovations in Immunotherapy: Unravelling the Trifecta - Precision Immunology, Cancer Microbiome, and CAR-T Cell Therapy for Personalized Cancer Treatment	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES
Keynote Presentation- CAR T-cell immunotherapy of solid tumours: moving through the generations John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio	09:00 - 09:30
CAR-T therapies, promises, current limitation and our vision into this space Georges Rawadi, CEO, Celyad Oncology	09:30 - 10:00
Presentation by Senior Representative, Volition	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Reserved Slot for Silver Sponsor	11:15 - 11:45
Reserved Slot for Bronze Sponsor	11:45 - 12:15
Bispecific T-Cell engagers for cancer immunotherapy	12:15 - 12:45
T cell mechanostimulation as a promising approach for enhancing immunotherapies Dr. Sebastian Lickert, Group Lead, ETH Zürich	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY
Solution Provider Presentation	14:15 - 14:45
A novel Neuropilin-1 (NRP1) antisense oligonucleotide (ASO) with strong in vivo antitumor activity as single agent and in combination with immune checkpoint inhibitors Konstantin Petropoulos, Chief Business Officer, Secarna Pharmaceuticals	14:45 - 15:15
Improving efficacy of CPI’s by selected combination therapy	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Development of a novel cancer immunotherapy for HPV16+ HNSCC based on recombinant arenavirus vectors Henning Lauterbach, Vice President, Preclinical & Translational Research, HOOKIPA Pharma Inc.	16:30 - 17:00
Oncolytic viruses in the era of Checkpoint Blockade	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION
Keynote Presentation	09:00 - 09:30
Strategies to optimize CDx in cancer	09:30 - 10:00
Solution Provider Presentation-Reserved for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Drug and CDx co-development with a therapeutic product	11:15 - 11:45
Solution Provider Presentation-Reserved for Silver Sponsor	11:45 - 12:15
CDx Launch Success: From Early Biomarker Development to Commercialization	12:15 - 12:45
Building up a successful CDx partnership with Pharma	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES
The Lymphocyte Stability Index - a pan-cancer biomarker for response to immune checkpoint blockade Robert Watson, Clinical Lecturer, University of Oxford	14:15 - 14:45
Innovative Safety Biomarker Applications to Drug Development	14:45 - 15:15
Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties	15:15 - 15:45
Closing Remarks from the Chairperson	15:45 - 15:50
END OF CONFERENCE	15:50 - 15:50

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY
Keynote Presentation: Real World & Single Cell Omics Data & Analytics for Precision Medicine Development Eike Staub, Head, Oncology Bioinformatics, Merck Healthcare, Germany	09:00 - 09:30
Personalized Cancer Immunotherapy Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca	09:30 - 10:00
Solution Provider Presentation-Reserved for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Generative AI designed Personalized Neoantigen Vaccines Daniela Kleine-Kohlbrecher, Senior Project Manager Immune Oncology, Evaxion Biotech	11:15 - 11:45
Solution Provider Presentation-Reserved for Silver Sponsor	11:45 - 12:15
Development of new generation DNA vaccines	12:15 - 12:45
Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
FUTURISTIC TRENDS IN IO RESEARCH
Future opportunities in clinical development of ICI’s	14:15 - 14:45
The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms	14:45 - 15:15
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care	15:15 - 15:45
Closing Remarks from the Chairperson	15:45 - 15:50